About Invokana® and other SGLT2 Inhibitors »

Invokana® (canagliflozin) is a drug prescribed to treat Type 2 diabetes. It belongs to a new class of drugs referred to as “Sodium Glucose co-transporter 2 (SGLT2) inhibitors.” Approved for sale by the FDA in 2013, Invokana® was the first of this new class to be sold in the United States. Invokana® and its related drugs, Invokamet and Invokamet XR are manufactured and sold by Johnson & Johnson and its subsidiary Janssen Pharmaceuticals. Other SGLT2 inhibitors - Farxiga® and Xigduo® XR (Astra Zeneca) and Jardiance® and Glyxambi® (Boehringer Ingelheim & Eli Lilly) – were subsequently approved for sale in the U.S. Each of these drugs comes in two forms: one as the sole drug and the other as a combination drug that includes the branded drug.

Invokana Amputations

Invokana® and SGLT2 Inhibitor Injury Risks »

In 2017 the FDA issued a Drug Safety Communication confirming that patients taking Invokana®, Invokamet® and Invokamet® XR are at an increased risk of leg and foot amputations and that the manufacturers (Johnson & Johnson and its subsidiary Janssen Pharmaceuticals) must include a “Black Box Warning” on the drugs’ labeling. The Drug Safety Communication was issued after the FDA reviewed data from two different clinical trials – the CANVAS and CANVAS-R studies. These data demonstrated that diabetes patients treated with Invokana®, Invokamet® and Invokamet® XR were twice as likely to require leg and foot amputations than those diabetes patients who were taking placebo (a non-drug). Also, on August 29, 2018 the FDA issued an urgent Safety Announcement to health care professionals and their patients. The Alert warned about the association between Invokana®, Invokamet®, Invokamet® XR, Jardiance®, Farxiga® and other SGLT2 diabetes medications and Fournier’s Gangrene, a life-threatening genital infection that can affect both men and women.

Case Evaluation

Case Evaluation »

We are currently accepting potential claims against the makers of Invokana®, Farxiga®, Jardiance® and other SGLT2 Inhibitors by users who have experienced serious adverse side effects including amputation of the legs, feet and/or toes, or Fournier’s Gangrene. If you or a loved one has been injured due to the use of Invokana®, Farxiga®, Jardiance® or any other SGLT2 Inhibitor, we would like to speak with you. Please call us toll-free at 1-888-276-3030 or send us your contact information and we will respond promptly.


Please fill in the form to request a FREE case evaluation from one of our attorneys if you or a loved one has suffered a Lower Limb Amputation or Fournier’s Gangrene (necrotizing fasciitis) while taking Invokana®, Invokamet® XR or other SGLT2 Inhibitors like Jardiance® or Farxiga®.

Have you or someone you know suffered a Lower Limb Amputation or Fournier’s Gangrene while taking Invokana®, Invokamet® XR or other SGLT2 Inhibitors like Jardiance® or Farxiga®? *
 All personal information will be kept private.

Reasons To Hire

  1. Our Mission is Excellence
  2. Thorough and diligent review and analysis of your case
  3. Proven Track Record
  4. Excellent Legal Representation
  5. Attention to Detail
  6. Dedication to our Craft
  7. Access to Leading Experts
  8. Updates on Litigation
  9. Concern for Your Well-being as well as Your Legal Rights
  10. No Fee Unless You Recover